Gold bars to be exempt from tariffs, White House clarifies
Willard D. Oberton, a director at Donaldson Co Inc. (NYSE:DCI), an $8.2 billion filtration solutions company, recently sold 7,000 shares of the company’s common stock on June 4, 2025. The shares were sold at a price of $69.51 each, resulting in a total transaction value of $486,570. Following this sale, Oberton now holds 29,661 shares directly. According to InvestingPro data, while this insider sale occurred, management has been actively buying back shares, and the company maintains a strong 29-year track record of consecutive dividend increases.
Additionally, Oberton exercised stock options to acquire 7,000 shares at a price of $28.43 per share earlier the same day. This transaction, classified differently, amounted to a total of $199,010. These moves are part of a series of transactions reported in a Form 4 filing with the Securities and Exchange Commission. The stock currently trades near $70.25, with a healthy financial profile as evidenced by its "Good" overall health score from InvestingPro’s comprehensive analysis.
In other recent news, Donaldson Company has reported a robust fiscal third-quarter performance for 2025, surpassing earnings expectations with an adjusted earnings per share (EPS) of $0.99, which was above the forecast of $0.95. The company’s revenue also slightly exceeded projections, reaching $940.1 million compared to the anticipated $936.84 million. Stifel analysts responded to this strong performance by raising the stock price target for Donaldson to $69, maintaining a Hold rating. The analysts noted the company’s resilience in its operating model and the strength of its aftermarket segments, particularly in the Mobile and Industrial sectors. Despite a $62 million impairment charge in its bioprocessing businesses, Donaldson improved its operating margin by 80 basis points. The company has projected a full-year total sales increase of 1-3%, with expectations of record sales, operating margin, and adjusted earnings. Donaldson’s strategic investments focus on life sciences and industrial markets, with significant emphasis on aftermarket business and regional manufacturing strategies to mitigate tariff impacts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.